AzTrials
AzTrials

Prosthetic Joint InfectionNCT06670885

New Molecular Approaches for Diagnosis of Prosthetic Joint Infection

An observational study of Prosthetic Joint Infection, run by I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio at 1 site in Italy.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

The goals of this observational study are: 1. to evaluate the concordance between traditional method (culture) and genomic method in diagnosing prosthetic joint infections; 2. to define an algorithm for laboratory diagnosis of prosthetic joint infections, which could be easily applied in our hospital setting; 3. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Prosthetic Joint Infection
How many people
70 participants
Where
1 siteItaly
Study dates
1 Oct 2024to 30 Sep 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: A total of 70 patients from the Department of Reconstructive Surgery and Osteoarticular Infections (CRIO) and the Hip Units of IRCCS Ospedale Galeazzi -Sant'Ambrogio for suspected infection of their prosthesis will be enrolled in the study.

Who may be able to join

  • Age >18 years
  • Males and females
  • Patients with a clinical indication for knee and hip revision surgery admitted at IRCCS Ospedale Galeazzi - Sant'Ambrogio

Who cannot join

  • Insufficient amount of periprosthetic tissue and synovial fluid collected
  • Patients unable to sign the Informed Consent
  • Pregnancy and breast feeding with declaration of patient
  • Age <18 years

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Italy1 site
  • IRCCS Ospedale Galeazzi-Sant'Ambrogio

    Milan, Milano, 20157

Other trials in Italy

About this study

Official title: Innovative Molecular Approaches for the Diagnosis of Prosthetic Joint Infections

The goals of this observational study are:

  1. to evaluate the concordance between traditional method (culture) and genomic method in diagnosing prosthetic joint infections;
  2. to define an algorithm for laboratory diagnosis of prosthetic joint infections, which could be easily applied in our hospital setting;
  3. to test different DNA extraction protocols to obtain high yields of microbial nucleic acids from infected human tissue samples.
Read the detailed description

Subjects A total of 70 patients from the Department of Reconstructive Surgery and Osteoarticular Infections (CRIO) and the Hip Units of IRCCS Ospedale Galeazzi -Sant'Ambrogio for suspected infection of their prosthesis will be enrolled in the study. Each sample will be analized with both traditional culture and Next Generation Sequencing (NGS).

On the basis of culture results patients will be divided into 3 groups.

Sample collection for Molecular analysis Sampling from peri-prosthetic tissue with macroscopic signs of infection will be taken from the synovial membrane, bone-prosthetic interface and intramedullary canals. Synovial fluid will be sterilely collected in DNAse and RNAse free containers for NGS analysis before performing the arthrotomy. Sterile swabs and pads will be used to collect samples from interface between tissue and bone implant and from intramedullary canal for NGS analysis. Bone tissue will be collected with new sterile instrumentation. Samples will be frozen within 2 hours from collection at -80°C until .

Sample collection for culture Sample collection of periprosthetic tissues and implant will be performed during the surgery after the proper exposure of the affected site. Synovial fluid will be collected in sterile screw cap tubes. Periprosthetic tissues and implant will be collected in sterile containers by using new sterile instrumentation. All samples will be sent to the Laboratory within 2 hours from collection. Samples after treatment with 0.1% (w:v) Dithiothreitol to dislodge bacteria from biofilm will be cultured on agar plates and broth for aerobes and anaerobes for 15 days. Microbial identification will be performed by biochemical assays.

A further tissue sample, collected in a separate sterile screw cap tube, will be used for host DNA removal to isolate microbial DNA, for shotgun NGS. Samples will be treated with saponin and/or different commercial kits for microbial DNA extraction. The dsDNA will be quantified with a Qubit fluorometer, and its purity will be determined with a nanodrop spectophotometer.

Synovial fluid analysis Synovial fluid for leukocyte count and differential will be collected in EthylenDiaminoTetraAcetic Acid (EDTA) containing tubes and analyzed by means of a Sysmex XN haematological analyser.

Determination of synovial protein, glucose, C-Reactive Protein (CRP) and leukocyte esterase will be performed on synovial fluid collected in clot activator containing tubes. Measurement of proteins, glucose and CRP will be carried out on Atellica CH and IM analyser (Siemens) while leukocyte esterase was determined by used of strips for urinalysis.

Molecular analysis 70 samples will be sent to a specialized laboratory which will perform nucleic acid extraction from biological specimen types using tailored proprietary techniques that include concentrating cellular material, mechanical lysis, and removing organic inhibitors and human host DNA. Every specimen will be processed with a positive and negative extraction control to assure quality.

At the end of the study any residual biological material will be destroyed

Statistical methodology Sample size The sample size has been calculated considering as the primary outcome the agreement of the innovative molecular method and the traditional culture of periprostethic tissue and synovial fluid in defining a patients as positive or negative for prosthetic joint infections . Based on investigators experience, the proportion of patients, undergoing revision surgery for knee and hip implant failure in IRCCS Ospedale Galeazzi Sant'Ambrogio with diagnosis of prosthetic joint infection based on cultural exam is of 45%. Considering a margin of error of 15%, an alpha = 0.05 and power = 80%, the number of patients to be tested is 70.

Analysis methodology Categorical data will be described as absolute and relative frequencies, while continuous data will be described as mean and 95%-confidence interval, if normally distributed, or as median and interquartile range, in case of non-normal distribution. Normal distribution will be assessed by the Shapiro-Wilk test.

Differences in proportion will be evaluated by Fisher's exact test or Chi-squared test; continuous variable comparison among the three groups will be performed using One-Way Analysis Of Variance (ANOVA) test for normally distributed data or with Kruskal-Wallis test, in case of non-normal distribution.

Agreement between molecular methods with traditional culture of periprostethic tissue and synovial fluid will be tested using Choen's kappa.

Sensitivity and specificity of each assay will be also assessed.

Keywords
Diagnosis of prosthetic joint infections, molecular methods

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06670885
Study groupRoleWhat they receive
Group APatients with diagnosis of infection confirmed by culture results
Group BPatients with diagnosis of prosthetic joint infection according to criteria of the MusculoSkeletal Infection Society (MSIS) but with negative culture
Group CPatients with no evidence of prosthetic joint infection according to criteria of MusculoSkeletal Infection Society (MSIS) (negative controls)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Concordance between analytical methods

    Concordance between methods will be analyzed by

    1. Patient categorization (Infected/not infected)
    2. Microorganisms identification

    Measured: 24 months

Secondary outcomes (1)
  1. Definition of an algorithm for laboratory diagnosis of prosthetic joint infections

    Results will be used for development of an algorithm for definition of workflow for diagnosis of prostehtic joint infections

    Measured: 36 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Nov 2024
  2. Study start1 Oct 2024
  3. Primary completion30 Sep 2027 (estimated)
  4. Study completion30 Sep 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
70 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06670885
Sponsor's protocol ID
Merian
Other IDs
L2071
Status last verified
Oct 2024
First submitted
29 Oct 2024
Last updated
1 Nov 2024
Results posted
No
Data monitoring committee
No
Individual data sharing
Yes: Only data useful for publication will be made avalilable

Publications

  • Kullar R, Chisari E, Snyder J, Cooper C, Parvizi J, Sniffen J. Next-Generation Sequencing Supports Targeted Antibiotic Treatment for Culture Negative Orthopedic Infections. Clin Infect Dis. 2023 Jan 13;76(2):359-364. doi: 10.1093/cid/ciac733.

    PubMed 36074890
  • Tsikopoulos K, Meroni G. Periprosthetic Joint Infection Diagnosis: A Narrative Review. Antibiotics (Basel). 2023 Sep 27;12(10):1485. doi: 10.3390/antibiotics12101485.

    PubMed 37887186
  • Salar-Vidal L, Chaves C, Dianzo-Delgado IT, Favier P, Giner-Almaraz S, Gomez-Gomez MJ, Martin-Gutierrez G, Pereira I, Rodriguez-Fernandez A, Ruiz-Garbajosa P, Salas-Venero C, Esteban J. Multicenter evaluation of BioFire JI panel related to improved microbiological diagnostics on acute osteoarticular infections. Int J Med Microbiol. 2023 Nov;313(6):151588. doi: 10.1016/j.ijmm.2023.151588. Epub 2023 Oct 31.

    PubMed 37925748
  • Villa F, Toscano M, De Vecchi E, Bortolin M, Drago L. Reliability of a multiplex PCR system for diagnosis of early and late prosthetic joint infections before and after broth enrichment. Int J Med Microbiol. 2017 Sep;307(6):363-370. doi: 10.1016/j.ijmm.2017.07.005. Epub 2017 Jul 18.

    PubMed 28750797
  • Mortazavi SM, Schwartzenberger J, Austin MS, Purtill JJ, Parvizi J. Revision total knee arthroplasty infection: incidence and predictors. Clin Orthop Relat Res. 2010 Aug;468(8):2052-9. doi: 10.1007/s11999-010-1308-6.

    PubMed 20309657
  • Tan TL, Kheir MM, Shohat N, Tan DD, Kheir M, Chen C, Parvizi J. Culture-Negative Periprosthetic Joint Infection: An Update on What to Expect. JB JS Open Access. 2018 Jul 12;3(3):e0060. doi: 10.2106/JBJS.OA.17.00060. eCollection 2018 Sep 25.

    PubMed 30533595
  • Murphy MP, MacConnell AE, Killen CJ, Schmitt DR, Wu K, Hopkinson WJ, Brown NM. Prevention Techniques Have Had Minimal Impact on the Population Rate of Prosthetic Joint Infection for Primary Total Hip and Knee Arthroplasty: A National Database Study. J Arthroplasty. 2023 Jun;38(6):1131-1140. doi: 10.1016/j.arth.2023.02.059. Epub 2023 Feb 27.

    PubMed 36858132

Questions about this trial

What is this clinical trial studying?

An observational study of Prosthetic Joint Infection, run by I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 1 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Concordance between analytical methods (time frame: 24 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06670885, which also lists 7 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Nov 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in